诊断学理论与实践 ›› 2026, Vol. 25 ›› Issue (03): 327-336.doi: 10.16150/j.1671-2870.2026.03.009
窦剑明a, 吴春晓a,*, 陈蕾b, 庞怡a, 施燕c(
), 顾凯a(
)
收稿日期:2025-12-10
修回日期:2026-02-08
接受日期:2026-02-10
出版日期:2026-06-25
发布日期:2026-06-27
通讯作者:
施燕 E-mail:shiyan@scdc.sh.cn;作者简介:作者贡献/Authors’ Contributions
窦剑明负责数据分析与解读,以及文章的构思、设计和起草撰写;吴春晓负责数据分析与解读,以及文章的构思、设计;陈蕾、庞怡负责数据资料收集;施燕、顾凯负责文章审阅与编辑。
*:并列第一作者
基金资助:
DOU Jianminga, WU Chunxiaoa,*, CHEN Leib, PANG Yia, SHI Yanc(
), GU Kaia(
)
Received:2025-12-10
Revised:2026-02-08
Accepted:2026-02-10
Published:2026-06-25
Online:2026-06-27
摘要:
目的:分析2002年至2019年上海市的肺癌发病及死亡情况,并观察其变化趋势。方法:采用上海市疾病预防控制中心建立的人群基础肿瘤登记管理系统和全死因登记系统中2002年至2019年上海市肺癌的发病和死亡资料,按诊断或死亡年份、性别和年龄组等因素分层分析,计算发病人数、构成比、粗率、年龄别率、年龄标准化率(简称标化率)等指标。标化率应用Segi’s 1960年世界标准人口构成调整计算。应用Joinpoint软件对不同分组的标化率、年龄别率和新发病例的部分诊断特征分类构成比,进行年度变化百分比趋势分析。结果:上海市肺癌的年新发病例数从2002年的8 005例,逐年增长到2019年的21 835例,标化发病率从33.73/10万上升至63.82/10万,年死亡人数从6 871人逐年增长到9 573人,标化死亡率从27.90/10万减少至21.75/10万。2019年,上海市肺癌标化发病率为63.82/10万,男性为66.37/10万,女性为62.09/10万;标化死亡率为21.75/10万,男性为33.50/10万,女性为10.95/10万,男女间差异均有统计学意义(P<0.001)。肺癌发病和死亡的年龄别数及率值总体上随着年龄的增长而增加。分性别的趋势分析显示,2002年至2019年,上海市男性肺癌的标化发病率以年均1.39%的增速上升(P=0.006),标化死亡率以年均0.98%的减速下降(P<0.001);女性肺癌的标化发病率在2002年至2011年间的变化无统计学意义(P=0.717),在2011年至2019年间则以年均15.57%的增速上升(P<0.001),标化死亡率在2002年至2012年间的变化无统计学意义(P=0.779),在2012年至2019年间则以年均2.95%的减速下降(P=0.011)。2002年至2019年上海肺癌新发病例通过病理确诊的占比从44.28%上升至61.88%,通过影像学检查确诊的占比从41.50%下降至7.99%;肺腺癌占比从19.66%上升至41.20%,鳞状细胞癌占比从14.13%下降至6.29%;Ⅰ期患者占比从3.76%上升至22.60%,Ⅱ期至Ⅳ期患者占比下降;但解剖部位、病理组织学分型和诊断时分期不明确的占比仍较高,2019年解剖部位未特指的占比为75.65%,病理组织学分型未特指的占比为45.89%,诊断时分期不明的比例为54.05%。结论:2019年,相比于全球,我国上海市的肺癌标化发病率相对较高,且不同性别、不同年龄间的死亡率呈现出差异较大的流行特征,2002年至2019年间女性肺癌发病率总体呈现上升趋势,2019年女性肺癌的标化发病率随着年龄增长而上升。本研究提示在肺癌的筛查、诊断和生存率提升上仍有较大的空间,为肺癌的进一步研究和预防控制提供了依据。
中图分类号:
窦剑明, 吴春晓, 陈蕾, 庞怡, 施燕, 顾凯. 2002年至2019年上海市肺癌发病和死亡情况分析[J]. 诊断学理论与实践, 2026, 25(03): 327-336.
DOU Jianming, WU Chunxiao, CHEN Lei, PANG Yi, SHI Yan, GU Kai. Incidence and mortality analysis of lung cancer in Shanghai from 2002 to 2019[J]. Journal of Diagnostics Concepts & Practice, 2026, 25(03): 327-336.
表1
2019年上海市肺癌发病和死亡概况
| Category | Gender | Rank | Number | Proportion /% | Crude rate /10-5 | ASR1 /10-5 | TASR2 /10-5 | Cumulative rate /% | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 35-64 years | 0-64 years | 0-74 years | 0-84 years | |||||||
| Incidence | Both | 1 | 21 835 | 23.80 | 148.87 | 63.82 | 107.90 | 3.81 | 7.83 | 11.54 |
| Male | 1 | 12 010 | 25.28 | 165.48 | 66.37 | 94.74 | 3.42 | 8.36 | 13.72 | |
| Female | 1 | 9 825 | 22.20 | 132.60 | 62.09 | 120.96 | 4.20 | 7.30 | 9.66 | |
| Mortality | Both | 1 | 9 573 | 25.25 | 65.27 | 21.75 | 20.96 | 0.77 | 2.58 | 5.58 |
| Male | 1 | 6 919 | 29.37 | 95.33 | 33.50 | 30.96 | 1.16 | 3.96 | 8.73 | |
| Female | 1 | 2 654 | 18.49 | 35.82 | 10.95 | 11.09 | 0.40 | 1.20 | 2.75 | |
表2
2002年至2019年上海市肺癌分性别的发病年龄别率变化趋势
| Age group/year | 2002 Rates(1/105) | Joinpoint | 2019 Rates(1/105) | Trend 1 | Trend 2 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | Rates(1/105) | Years | APC | t value | P value | Years | APC | t value | P value | ||||
| Male | |||||||||||||
| 20- | 0.43 | 2012 | 0.47 | 3.66 | 2002-2012 | -1.89 | -0.91 | 0.388 | 2012-2019 | 38.31 | 13.66 | <0.001 | |
| 25- | 0.75 | 2008 | 0.18 | 6.48 | 2002-2008 | -9.83 | -0.78 | 0.450 | 2008-2019 | 26.88 | 8.42 | <0.001 | |
| 30- | 2.97 | 2009 | 1.27 | 11.74 | 2002-2009 | -18.19 | -4.1 | 0.001 | 2009-2019 | 29.39 | 14.18 | <0.001 | |
| 35- | 5.99 | 2014 | 4.08 | 20.74 | 2002-2014 | -2.17 | -1.38 | 0.191 | 2014-2019 | 35.58 | 8.13 | <0.001 | |
| 40- | 15.98 | 2011 | 9.29 | 36.51 | 2002-2011 | -5.44 | -2.95 | 0.011 | 2011-2019 | 15.77 | 6.86 | <0.001 | |
| 45- | 33.66 | - | - | 48.67 | 2002-2019 | 1.77 | 3.64 | 0.002 | |||||
| 50- | 60.65 | - | - | 84.84 | 2002-2019 | 2.31 | 7.12 | <0.001 | |||||
| 55- | 116.51 | - | - | 176.50 | 2002-2019 | 3.66 | 8.57 | <0.001 | |||||
| 60- | 197.98 | 2013 | 177.80 | 292.84 | 2002-2013 | -0.68 | -1.12 | 0.285 | 2013-2019 | 9.55 | 9.49 | <0.001 | |
| 65- | 322.43 | - | - | 432.01 | 2002-2019 | 1.39 | 1.99 | 0.064 | |||||
| 70- | 503.26 | - | - | 556.68 | 2002-2019 | 0.17 | 0.33 | 0.747 | |||||
| 75- | 654.84 | 2011 | 510.15 | 582.61 | 2002-2011 | -2.30 | -4.41 | 0.001 | 2011-2019 | 0.78 | 1.26 | 0.230 | |
| 80- | 664.05 | 2009 | 639.08 | 489.54 | 2002-2009 | -0.04 | -0.06 | 0.955 | 2009-2019 | -2.47 | -6.73 | <0.001 | |
| ≥85 | 534.70 | 587.53 | 2002-2019 | -0.22 | -0.70 | 0.495 | |||||||
| Female | |||||||||||||
| 20- | 0.23 | 2010 | 0.20 | 6.06 | 2002-2010 | -11.97 | -0.92 | 0.381 | 2010-2019 | 43.24 | 6.19 | <0.001 | |
| 25- | 0.54 | 2011 | 1.14 | 19.16 | 2002-2011 | 8.03 | 1.31 | 0.211 | 2011-2019 | 45.20 | 13.48 | <0.001 | |
| 30- | 2.18 | 2010 | 1.70 | 36.63 | 2002-2010 | -5.45 | -1.28 | 0.221 | 2010-2019 | 41.53 | 20.52 | <0.001 | |
| 35- | 5.13 | 2012 | 6.68 | 56.96 | 2002-2012 | 4.23 | 1.23 | 0.241 | 2012-2019 | 38.88 | 12.48 | <0.001 | |
| 40- | 10.24 | 2012 | 12.45 | 91.64 | 2002-2012 | 3.21 | 1.89 | 0.081 | 2012-2019 | 32.45 | 17.05 | <0.001 | |
| 45- | 18.14 | 2010 | 16.58 | 110.24 | 2002-2010 | 0.53 | 0.31 | 0.762 | 2010-2019 | 22.54 | 19.61 | <0.001 | |
| 50- | 31.05 | 2009 | 30.96 | 123.20 | 2002-2009 | -0.14 | -0.07 | 0.944 | 2009-2019 | 15.72 | 18.41 | <0.001 | |
| 55- | 47.67 | 2010 | 45.42 | 175.50 | 2002-2010 | 1.10 | 0.80 | 0.440 | 2010-2019 | 14.90 | 22.20 | <0.001 | |
| 60- | 63.13 | 2011 | 75.70 | 219.69 | 2002-2011 | 1.49 | 0.76 | 0.459 | 2011-2019 | 14.72 | 12.06 | <0.001 | |
| 65- | 101.49 | 2013 | 113.55 | 288.16 | 2002-2013 | 0.73 | 0.57 | 0.578 | 2013-2019 | 17.11 | 8.40 | <0.001 | |
| 70- | 164.23 | 332.39 | 2002-2019 | 4.45 | 5.29 | <0.001 | |||||||
| 75- | 196.79 | - | - | 264.90 | 2002-2019 | 1.75 | 4.56 | <0.001 | |||||
| 80- | 221.31 | - | - | 206.51 | 2002-2019 | -0.14 | -0.49 | 0.628 | |||||
| ≥85 | 166.28 | - | - | 263.13 | 2002-2019 | 1.30 | 4.44 | <0.001 | |||||
表3
2002年至2019年上海市肺癌分性别的死亡年龄别率变化趋势
| Age group/year | 2002 Rates(1/105) | Joinpoint | 2019 Rates (1/105) | Trend 1 | Trend 2 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | Rates(1/105) | Years | APC | t value | P value | Years | APC | t value | P value | |||||
| Male | ||||||||||||||
| 30- | 1.37 | - | - | 1.07 | 2002-2019 | -5.52 | -3.04 | 0.008 | ||||||
| 35- | 2.27 | - | - | 1.41 | 2002-2019 | -2.89 | -2.46 | 0.025 | ||||||
| 40- | 10.70 | - | - | 4.11 | 2002-2019 | -4.71 | -4.92 | <0.001 | ||||||
| 45- | 24.54 | 2013 | 19.49 | 6.89 | 2002-2013 | -1.22 | -1.51 | 0.155 | 2013-2019 | -12.48 | -4.08 | 0.001 | ||
| 50- | 36.98 | 2014 | 49.04 | 18.29 | 2002-2014 | 2.92 | 4.38 | 0.001 | 2014-2019 | -15.67 | -5.64 | <0.001 | ||
| 55- | 85.93 | - | - | 61.51 | 2002-2019 | 0.80 | 1.28 | 0.219 | ||||||
| 60- | 138.73 | - | - | 136.99 | 2002-2019 | 0.65 | 2.21 | 0.042 | ||||||
| 65- | 254.10 | - | - | 220.70 | 2002-2019 | -0.8 | -2.05 | 0.057 | ||||||
| 70- | 439.48 | - | - | 339.90 | 2002-2019 | -1.32 | -4.22 | 0.001 | ||||||
| 75- | 640.52 | - | - | 453.04 | 2002-2019 | -1.70 | -9.55 | <0.001 | ||||||
| 80- | 759.46 | - | - | 500.79 | 2002-2019 | -1.73 | -5.58 | <0.001 | ||||||
| ≥85 | 688.67 | - | - | 663.36 | 2002-2019 | -0.33 | -0.91 | 0.374 | ||||||
| Female | ||||||||||||||
| 30- | 1.21 | - | - | 0.73 | 2002-2019 | -4.28 | -2.28 | 0.037 | ||||||
| 35- | 3.59 | - | - | 1.04 | 2002-2019 | -3.63 | -3.21 | 0.005 | ||||||
| 40- | 5.12 | - | - | 3.77 | 2002-2019 | -1.67 | -1.75 | 0.099 | ||||||
| 45- | 12.94 | - | - | 6.98 | 2002-2019 | -1.64 | -2.43 | 0.027 | ||||||
| 50- | 18.76 | - | - | 8.97 | 2002-2019 | -1.52 | -1.85 | 0.083 | ||||||
| 55- | 34.41 | - | - | 21.60 | 2002-2019 | -2.11 | -3.65 | 0.002 | ||||||
| 60- | 53.91 | - | - | 35.46 | 2002-2019 | -1.35 | -3.03 | 0.008 | ||||||
| 65- | 79.22 | - | - | 61.65 | 2002-2019 | -1.61 | -6.11 | <0.001 | ||||||
| 70- | 146.06 | - | - | 99.31 | 2002-2019 | -1.62 | -3.72 | 0.002 | ||||||
| 75- | 185.27 | 2014 | 183.85 | 130.35 | 2002-2014 | 0.14 | 0.22 | 0.829 | 2014-2019 | -6.45 | -2.58 | 0.023 | ||
| 80- | 213.82 | 2014 | 228.37 | 180.50 | 2002-2014 | 1.00 | 2.35 | 0.035 | 2014-2019 | -4.97 | -3.66 | 0.003 | ||
| ≥85 | 202.78 | - | - | 277.22 | 2002-2019 | 1.33 | 4.23 | <0.001 | ||||||
表4
2002年至2019年上海市肺癌诊断特征变化趋势
| Category | 2002 Percentage/% | Joinpoint | 2019 Percentage/% | Trend 1 | Trend 2 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | Percentage/% | Years | APC | t value | P value | Years | APC | t value | P value | |||||
| Diagnostic basis | ||||||||||||||
| Morphological verification | 44.28 | 61.88 | 2002-2019 | 3.12 | 9.29 | <0.001 | ||||||||
| Imaging verification | 41.50 | 2008 | 30.51 | 7.99 | 2002-2008 | -4.80 | -4.15 | 0.001 | 2008-2019 | 10.83 | -24.25 | <0.001 | ||
| Others | 14.22 | 30.14 | 2002-2019 | 1.62 | 2.24 | 0.040 | ||||||||
| Anatomic site | - | - | ||||||||||||
| Trachea, bronchus | 3.32 | - | - | 0.22 | 2002-2019 | -19.82 | -14.91 | <0.001 | ||||||
| Pulmonary lobes | 35.89 | - | - | 24.12 | 2002-2019 | -3.09 | -10.95 | <0.001 | ||||||
| Unspecified | 60.79 | - | - | 75.65 | 2002-2019 | 1.67 | 13.55 | <0.001 | ||||||
| Histological type | - | - | ||||||||||||
| Adenocarcinoma | 19.66 | - | - | 41.20 | 2002-2019 | 5.85 | 13.48 | <0.001 | ||||||
| Squamous-cell carcinoma | 14.13 | 2010 | 12.43 | 6.29 | 2002-2010 | -0.25 | -0.33 | 0.746 | 2010-2019 | -7.18 | -11.92 | <0.001 | ||
| Others | 4.03 | 2011 | 8.79 | 6.62 | 2002-2011 | 9.06 | 11.15 | <0.001 | 2011-2019 | -2.57 | -2.80 | 0.015 | ||
| Unspecified | 62.17 | - | - | 45.89 | 2002-2019 | -3.16 | -8.18 | <0.001 | ||||||
| Stage | - | - | ||||||||||||
| Ⅰ | 3.76 | 2010 | 6.38 | 22.60 | 2002-2010 | 8.32 | 5.87 | <0.001 | 2010-2019 | 16.46 | 13.36 | <0.001 | ||
| Ⅱ | 5.67 | 2010 | 4.94 | 2.59 | 2002-2010 | -1.33 | -1.14 | 0.227 | 2010-2019 | -7.14 | -7.50 | <0.001 | ||
| Ⅲ | 14.52 | 2009 | 13.62 | 4.88 | 2002-2009 | -0.79 | -1.03 | 0.321 | 2009-2019 | -9.24 | -21.79 | <0.001 | ||
| Ⅳ | 21.14 | 2011 | 30.51 | 15.88 | 2002-2011 | 4.76 | 11.09 | <0.001 | 2011-2019 | -7.61 | -15.80 | <0.001 | ||
| Unknown | 54.92 | 2010 | 47.65 | 54.05 | 2002-2010 | -2.41 | -5.19 | <0.001 | 2010-2019 | 1.33 | 3.37 | 0.005 | ||
| [1] | BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. |
| [2] | HAN B, ZHENG R, ZENG H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1):47-53. |
| [3] | 顾凯, 庞怡, 吴春晓, 等. 2017年上海市恶性肿瘤发病和死亡情况与2002-2017年的变化趋势分析[J]. 肿瘤, 2023, 43(4):241-256. |
| GU K, PANG YM WU C X. Analysis of the current status of cancer incidence and mortality in Shanghai,2017 and trends of 2002-2017[J]. Tumor, 2023, 43(4):241-256. | |
| [4] | 国家癌症中心. 中国肿瘤登记工作指导手册[M].人民卫生出版社, 2016. |
| National Cancer Center. Chinese guideline for cancer regi-stration[M]. People's Medical Publishing House, 2016. | |
| [5] | PARKIN D M, CHEN V W, FERLAY J, et al. Comparability and quality control in cancer registration. IARC Technical Report No.19[M]. Lyon: IARC Press,1994. |
| [6] | 上海市疾病预防控制中心. 上海市恶性肿瘤发病率、死亡率和生存率(2001-2012)[M] 上海: 上海科学普及出版社,2017:1-6. |
| Shanghai Municipal Center For Disease Control & Prevention. Cancer incidence, mortality and survival rates in Shanghai (2001-2012)[M]. Shanghai: Shanghai General Science Press,2017:1-6. | |
| [7] | TRAVIS W D, BRAMBILLA E, BURKE A P, et al. WHO classification of tumours of the lung, pleura, thymus and heart[M]. Geneva: WHO Press, 2015. |
| [8] | 卢伟, 郑莹. 肿瘤命名与编码[M]. 上海: 第二军医大学出版社, 2011. |
| LU W, ZHENG Y. Tumor nomenclature and coding[M]. Shanghai: Second Military Medical University Press, 2011. | |
| [9] | SEGI M, NIPPON T K, TŌHOKU D I. Cancer mortality for selected sites in 24 countries (1950-1957)[M]. Sendai, Japan: Japan Cancer Society,1960. |
| [10] | Statistical Research and Applications Branch, National Cancer Institute. Joinpoint Regression Program, Version 4.8.0.1[CP]. April, 2020. |
| [11] |
KIM H J, FAY M P, FEUER E J, et al. Permutation tests for joinpoint regression with applications to cancer rates[J]. Statist Med, 2000, 19(3):335-351.
doi: 10.1002/(ISSN)1097-0258 URL |
| [12] | 窦剑明, 吴春晓, 庞怡, 等. 2016年上海市肺癌发病和死亡的特征及其在2002-2016年的变化趋势[J]. 肿瘤, 2023, 43(4):266-276. |
| DOU J M, WU C X, PANG Y, et al. The incidence and mortality of lung cancer in 2016 and their trends from 2002 to 2016 in Shanghai[J]. Tumor, 2023, 43(4): 266-276. | |
| [13] |
XIE D, ZHANG L, HE N, et al. Overdiagnosis of lung cancer due to the introduction of low-dose computed tomography in average-risk populations in the people’s republic of China[J]. J Thorac Oncol, 2025, 20(7):884-896.
doi: 10.1016/j.jtho.2025.02.013 URL |
| [14] |
National Lung Screening Trial Research Team, ABERLE D R, ADAMS A M, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening[J]. N Engl J Med, 2011, 365(5):395-409.
doi: 10.1056/NEJMoa1102873 URL |
| [15] |
ZHOU Q, FAN Y, WU N, et al. Demonstration program of population-based lung cancer screening in China: Rationale and study design[J]. Thorac Cancer, 2014, 5(3):197-203.
doi: 10.1111/1759-7714.12078 pmid: 26767001 |
| [16] |
LUO X, ZHENG S, LIU Q, et al. Should nonsmokers be excluded from early lung cancer screening with low-dose spiral computed tomography? Community-based practice in Shanghai[J]. Transl Oncol, 2017, 10(4):485-490.
doi: S1936-5233(17)30019-0 pmid: 28521182 |
| [17] | YANG W, QIAN F, TENG J, et al. Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening[J]. Lung Cancer, 2018,117:20-26. |
| [18] | LIANG F, WU C, GU H, et al. Lung cancer incidence in female rises significantly in urban sprawl of Shanghai after introduction of LDCT screening[J]. Lung Cancer, 2019,132:114-118. |
| [19] |
张敏璐, 吴春晓, 龚杨明, 等. 上海人群肺癌生存率分析[J]. 中国癌症杂志, 2017, 27(5):326-333.
doi: 10.19401/j.cnki.1007-3639.2017.05.002 |
|
ZHANG M L, WU C X, GONG Y M, et al. Survival analysis of patients with lung cancer in Shanghai[J]. Chin Oncol, 2017, 27(5):326-333.
doi: 10.19401/j.cnki.1007-3639.2017.05.002 |
|
| [20] |
SACHER A G, DAHLBERG S E, HENG J, et al. Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer[J]. JAMA Oncol, 2016, 2(3):313.
doi: 10.1001/jamaoncol.2015.4482 pmid: 26720421 |
| [21] |
KO Y H, KIM S J, KIM W S, et al. Risk factors for primary lung cancer among never-smoking women in South Korea: A retrospective nationwide population-based cohort study[J]. Korean J Intern Med, 2020, 35(3):692-702.
doi: 10.3904/kjim.2019.283 pmid: 32066220 |
| [22] |
WU X, ZHU B, ZHOU J, et al. The epidemiological trends in the burden of lung cancer attributable to PM2.5 exposure in China[J]. BMC Public Health, 2021, 21(1):737.
doi: 10.1186/s12889-021-10765-1 |
| [23] |
FUENTES N, SILVA RODRIGUEZ M, SILVEYRA P. Role of sex hormones in lung cancer[J]. Exp Biol Med (Maywood), 2021, 246(19):2098-2110.
doi: 10.1177/15353702211019697 URL |
| [24] |
MIRANDA-FILHO A, PIÑEROS M, BRAY F. The descriptive epidemiology of lung cancer and tobacco control: a global overview 2018[J]. Salud Publica Mex, 2019; 61(3):219-229.
doi: 10.21149/10140 URL |
| [25] | SONG M A, BENOWITZ N L, BERMAN M, et al. Cigarette filter ventilation and its relationship to increasing rates of lung adenocarcinoma[J]. JNCI J Natl Cancer Inst, 2017, 109(12):djx075. |
| [26] | LUO W, ZENG Z, JIN Y, et al. Distinct immune microenvironment of lung adenocarcinoma in never-smokers from smokers[J]. Cell Rep Med, 2023, 4(6):101078. |
| [27] |
SUN Y, REN Y, FANG Z, et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases[J]. J Clin Oncol, 2010, 28(30):4616-4620.
doi: 10.1200/JCO.2010.29.6038 pmid: 20855837 |
| [28] |
CHEN J, YANG H, TEO A S M, et al. Genomic landscape of lung adenocarcinoma in East Asians[J]. Nat Genet, 2020, 52(2):177-186.
doi: 10.1038/s41588-019-0569-6 pmid: 32015526 |
| [29] | MIDHA A, DEARDEN S, MCCORMACK R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethni-city (mutMapⅡ). Am J Cancer Res. 2015; 5(9):2892-2911. |
| [30] |
LEITER A, VELUSWAMY R R, WISNIVESKY J P. The global burden of lung cancer: Current status and future trends[J]. Nat Rev Clin Oncol, 2023, 20(9):624-639.
doi: 10.1038/s41571-023-00798-3 pmid: 37479810 |
| [31] | 郑杨, 王春芳, 吴春晓, 等. 《“健康上海2030”规划纲要》三项主要指标解读[J]. 上海预防医学, 2018, 30(1):11-14,20. |
| ZHENG Y, WANG C F, WU C X, et al. Interpretation of three main indicators of the "2030 Plan for Healthy Shanghai"[J]. Shanghai J Prev Med, 2018, 30(1):11-14,20. |
| [1] | 王莉莉, 郭建. 2015年至2025年中国无绿藻病流行现状及耐药调查[J]. 诊断学理论与实践, 2026, 25(03): 308-314. |
| [2] | 文斌, 朱宏, 刘师, 秦飞雪, 何娟坤, 桂莉. PD-1抑制剂导致暴发性1型糖尿病酮症酸中毒1例报告并文献复习[J]. 诊断学理论与实践, 2026, 25(02): 232-238. |
| [3] | 蔡姣迪, 陈国群, 张文琴. 2025年NCCN非小细胞肺癌临床实践(V1-V3)指南解读[J]. 诊断学理论与实践, 2026, 25(01): 37-43. |
| [4] | 谢香梅, 韩英, 苏娟, 衡伟. 肺癌精囊腺转移病例一例报道[J]. 诊断学理论与实践, 2026, 25(01): 96-99. |
| [5] | 周晓蝶, 戚荣鑫, 王璇, 余波, 王建军, 石群立, 饶秋, 鲍炜. 尿路上皮癌PD-L1、AR及P53表达及其与临床预后相关性[J]. 诊断学理论与实践, 2025, 24(03): 286-292. |
| [6] | 杜雅洁, 王铭飞, 林茂松. 结直肠癌中KIAA1429通过上调PD-L1及下调CD8+ T细胞组织浸润而抑制抗肿瘤免疫的研究[J]. 诊断学理论与实践, 2025, 24(03): 301-311. |
| [7] | 吴琪, 范伯男, 李岩. 2022全球癌症统计报告分析解读:中国与世界癌症疾病负担与流行趋势[J]. 诊断学理论与实践, 2025, 24(02): 135-145. |
| [8] | 陈微微, 孙良丹. 中国人群银屑病遗传流行病学研究进展[J]. 诊断学理论与实践, 2024, 23(06): 561-567. |
| [9] | 范伯男, 李岩. 全球主要疾病负担及健康状况趋势分析——1990年至2021年全球疾病和伤害负担报告解读[J]. 诊断学理论与实践, 2024, 23(05): 474-483. |
| [10] | 张志萍, 蔡世龙, 耿延龙, 刘世友. 2000—2022年上海市宝山区甲状腺癌发病趋势分析[J]. 诊断学理论与实践, 2024, 23(04): 378-384. |
| [11] | 章新, 郑莹. 2005—2020年中国国家及分省疾病监测点的肿瘤死亡疾病负担数据解读[J]. 诊断学理论与实践, 2024, 23(04): 371-377. |
| [12] | 王刚, 齐金蕾, 刘馨雅, 任汝静, 林绍慧, 胡以松, 李海霞, 谢心怡, 王金涛, 李建平, 朱怡康, 高梦伊, 杨竣杰, 王怡然, 井玉荣, 耿介立, 支楠, 曹雯炜, 徐群, 余小萍, 朱圆, 周滢, 王琳, 高超, 李彬寅, 陈生弟, 袁芳, 窦荣花, 刘晓云, 李雪娜, 尹雅芙, 常燕, 徐刚, 辛佳蔚, 钟燕婷, 李春波, 王颖, 周脉耕, 陈晓春, 代表中国阿尔茨海默病报告编写组. 中国阿尔茨海默病报告2024[J]. 诊断学理论与实践, 2024, 23(03): 219-256. |
| [13] | 张冬燕, 李燕. 世界卫生组织《全球高血压报告》(2023年)概要及解读[J]. 诊断学理论与实践, 2024, 23(03): 297-304. |
| [14] | 刘娟, 殷丽娟, 范德生. AR、SKP2、SOX10、PD-L1及TIL表达在三阴性乳腺癌中的意义[J]. 诊断学理论与实践, 2024, 23(02): 162-172. |
| [15] | 邵新淋, 朱雪梅, 曹华. 结缔组织病相关间质性肺疾病危险因素及发病机制研究进展[J]. 诊断学理论与实践, 2024, 23(02): 202-209. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||